Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Adherent-invasive Escherichia coli (AIEC) surface structures, most notably Type 1 pili and flagella, are essential for the pathogenesis of Crohn's disease by enabling bacterial attachment to and invasion of the intestinal epithelium [PMID: 24859503]. The FimH adhesin, located at the tip of Type 1 pili, specifically recognizes and binds to mannosylated residues on the host receptor Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6), which is overexpressed in the ileal mucosa of affected individuals [PMID: 15542707]. This interaction facilitates the formation of biofilms and the subsequent translocation of bacteria into the lamina propria, where they survive within macrophages and drive chronic inflammation [PMID: 21903790]. Therapeutic targeting of these surface structures, particularly through small-molecule FimH antagonists like Sibofimloc (EB8018/TAK-018), represents a novel anti-adhesive approach designed to clear pathogenic AIEC while sparing the commensal microbiota [PMID: 31513025]. By blocking the initial step of infection, these agents aim to prevent the inflammatory cascade and mucosal damage associated with Crohn's disease [PMID: 28607163].
Anti-adhesive mechanism involving the competitive inhibition of the bacterial FimH adhesin, preventing its interaction with host CEACAM6 receptors and subsequent mucosal colonization [PMID: 31513025].
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Adherent-invasive Escherichia coli surface structures.